Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Elanco Animal Health has received a consensus rating of "Moderate Buy" from nine brokerages, with an average 12-month price target of $17.33.
• The company reported earnings of $0.26 per share for the last quarter, beating expectations, and indicated a revenue increase of 4.8% compared to the previous year.
• Institutional investors own 97.48% of Elanco's stock, highlighting strong institutional confidence in the company.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has received an average rating of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $17.3333.

ELAN has been the topic of several research reports. Stifel Nicolaus upped their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Zacks Research downgraded Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Finally, Piper Sandler increased their price target on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently modified their holdings of ELAN. Ameriprise Financial Inc. grew its position in shares of Elanco Animal Health by 127.5% during the 4th quarter. Ameriprise Financial Inc. now owns 97,373 shares of the company's stock valued at $1,179,000 after acquiring an additional 54,581 shares during the period. Cetera Investment Advisers grew its position in shares of Elanco Animal Health by 17.2% during the 4th quarter. Cetera Investment Advisers now owns 31,004 shares of the company's stock valued at $375,000 after acquiring an additional 4,553 shares during the period. Lazard Asset Management LLC grew its position in shares of Elanco Animal Health by 644.3% during the 4th quarter. Lazard Asset Management LLC now owns 29,006 shares of the company's stock valued at $350,000 after acquiring an additional 25,109 shares during the period. Nomura Holdings Inc. acquired a new stake in shares of Elanco Animal Health during the 4th quarter valued at about $177,000. Finally, State of Wyoming grew its position in shares of Elanco Animal Health by 23.4% during the 4th quarter. State of Wyoming now owns 15,236 shares of the company's stock valued at $185,000 after acquiring an additional 2,892 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Up 0.4%

Shares of ELAN traded up $0.08 during midday trading on Wednesday, hitting $19.18. 8,550,435 shares of the company's stock traded hands, compared to its average volume of 10,031,933. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $19.26. The firm's fifty day moving average is $16.77 and its 200-day moving average is $13.45. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of 22.30, a price-to-earnings-growth ratio of 3.54 and a beta of 1.62.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the prior year, the firm earned $0.30 EPS. The firm's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.